Dorsey Wright & Associates Has $2.89 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dorsey Wright & Associates cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.5% during the 4th quarter, HoldingsChannel reports. The fund owned 130,887 shares of the company’s stock after selling 37,975 shares during the quarter. Dorsey Wright & Associates’ holdings in Teva Pharmaceutical Industries were worth $2,885,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of TEVA. Stifel Financial Corp grew its position in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after buying an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP bought a new position in Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. Asset Management One Co. Ltd. raised its holdings in Teva Pharmaceutical Industries by 14.6% in the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $3,340,000. 54.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on TEVA shares. UBS Group dropped their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Barclays reduced their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Bank of America lowered their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $15.06 on Friday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The firm has a market cap of $17.07 billion, a PE ratio of -10.38, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The firm’s fifty day moving average is $17.21 and its 200-day moving average is $18.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.